EUCTR2007-005994-79-ES进行中（未招募）不适用
Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes con enfermedad de Alzheimer de grado leve a moderado que no son portadores de la apolipoproteína E (ApoE) e4A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 Non-carriers
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development0 个研究点目标入组 1,250 人开始时间: 2008年2月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed and dated written informed consent obtained from the subject or the subject’s legally acceptable representative (if applicable) in accordance with the local regulations. The subject’s caregiver must also consent to participate in the study.
- •2) Man or surgically sterile or postmenopausal woman, aged =50 to <89 years.
- •3) Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
- •4) MMSE score of 16 to 26, inclusive.
- •5) Rosen Modified Hachinski Ischemic Score =4.
- •6) Lives at home with appropriate caregiver capable of accompanying the subject on all clinic visits, or community dwelling with caregiver capable of accompanying the subject on all clinic visits and visiting with the subject approximately 5 times per week for the duration of the study.
- •7) Screening visit brain MRI scan consistent with the diagnosis of AD.
- •8) Fluency in local language and evidence of adequate premorbid intellectual functioning.
- •9) Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- •10) Receiving stable doses of medication(s) for the treatment of nonexcluded medical condition(s) for at least 30 days prior to screening, and, if treated with cholinesterase inhibitors and/or memantine, all of the following conditions are also met: (a) The subject is maintained on a stable dose regimen for at least 120 days prior to screening. (b) The subject is free of any clinically important side effects attributable to the drug. (c) The subject and caregiver agree that, barring unforeseen circumstances, they will continue the same regimen for the duration of the trial.
- •11) The subject and caregiver are likely to be able to participate in all scheduled evaluations and complete all required tests.
- •12) Willing to undergo apolipoprotein E (ApoE) testing and agree to disclosure of ApoE4 status.
- •13) Noncarrier of ApoE4 according to genotyping at screening (ie, has zero copies of ApoE4).
- •14) In the opinion of the investigator, the subject and caregiver will be compliant and have a high probability of completing the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •1) Signed and dated written informed consent obtained from the subject or the subject’s legally acceptable representative (if applicable) in accordance with the local regulations. The subject’s caregiver must also consent to participate in the study.
- •2) Man or surgically sterile or postmenopausal woman, aged =50 to <89 years.
- •3) Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
- •4) MMSE score of 16 to 26, inclusive.
- •5) Rosen Modified Hachinski Ischemic Score =4.
- •6) Lives at home with appropriate caregiver capable of accompanying the subject on all clinic visits, or community dwelling with caregiver capable of accompanying the subject on all clinic visits and visiting with the subject approximately 5 times per week for the duration of the study.
- •7) Screening visit brain MRI scan consistent with the diagnosis of AD.
- •8) Fluency in local language and evidence of adequate premorbid intellectual functioning.
- •9) Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- •10) Receiving stable doses of medication(s) for the treatment of nonexcluded medical condition(s) for at least 30 days prior to screening, and, if treated with cholinesterase inhibitors and/or memantine, all of the following conditions are also met: (a) The subject is maintained on a stable dose regimen for at least 120 days prior to screening. (b) The subject is free of any clinically important side effects attributable to the drug. (c) The subject and caregiver agree that, barring unforeseen circumstances, they will continue the same regimen for the duration of the trial.
- •11) The subject and caregiver are likely to be able to participate in all scheduled evaluations and complete all required tests.
- •12) Willing to undergo apolipoprotein E (ApoE) testing and agree to disclosure of ApoE4 status.
- •13) Noncarrier of ApoE4 according to genotyping at screening (ie, has zero copies of ApoE4).
- •14) In the opinion of the investigator, the subject and caregiver will be compliant and have a high probability of completing the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Significant neurologic disease, other than AD, that may affect cognition.
- •2) Screening visit brain MRI scan indicative of any other significant abnormality, including but not limited to multiple microhemorrhages, evidence of a single prior hemorrhage >1 cm3, multiple lacunar infarcts or evidence of a single prior infarct >1 cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or space-occupying lesions (eg, arachnoid cysts or brain tumors, such as meningioma).
- •3) Current presence of a clinically important major psychiatric disorder (eg, major depressive disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) or symptom (eg, hallucinations) that could affect the subject’s ability to complete the study.
- •4) Current clinically important systemic illness that is likely to result in deterioration of the subject’s condition or affect the subject’s safety during the study.
- •5) History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis or plaque.
- •6) History of seizures, excluding febrile seizures in childhood.
- •7) Weight greater than 120 kg (264 lb).
- •8) History or evidence of any clinically important autoimmune disease or disorder of the immune system (eg, Crohn disease, rheumatoid arthritis).
- •9) Clinically important infection within the last 30 days (eg, chronic persistent or acute infection, such as bronchitis or urinary tract infection [UTI]).
- •10) Treatment with immunosuppressive medications (eg, systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
- •11) Myocardial infarction within the last 2 years.
- •12) History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma, and squamous cell carcinoma of the skin.
- •13) Uncontrolled hypertension within 6 months prior to screening.
- •14) Other clinically important abnormality on vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (eg, atrial fibrillation) that could compromise the study or be detrimental to the subject.
- •15) Hemoglobin level less than 11 g/dL.
- •1) Significant neurologic disease, other than AD, that may affect cognition.
- •2) Screening visit brain MRI scan indicative of any other significant abnormality, including but not limited to multiple microhemorrhages, evidence of a single prior hemorrhage >1 cm3, multiple lacunar infarcts or evidence of a single prior infarct >1 cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or space-occupying lesions (eg, arachnoid cysts or brain tumors, such as meningioma).
- •3) Current presence of a clinically important major psychiatric disorder (eg, major depressive disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) or symptom (eg, hallucinations) that could affect the subject’s ability to complete the study.
- •4) Current clinically important systemic illness that is likely to result in deterioration of the subject’s condition or affect the subject’s safety during the study.
- •5) History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis or plaque.
- •6) History of seizures, excluding febrile seizures in childhood.
- •7) Weight greater than 120 kg (264 lb).
- •8) History or evidence of any clinically important autoimmune disease or disorder of the immune system (eg, Crohn disease, rheumatoid arthritis).
- •9) Clinically important infection within the last 30 days (eg, chronic persistent or acute infection, such as bronchitis or urinary tract infection [UTI]).
- •10) Treatment with immunosuppressive medications (eg, systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
- •11) Myocardial infarction within the last 2 years.
- •12) History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma, and squamous cell carcinoma of the skin.
- •13) Uncontrolled hypertension within 6 months prior to screening.
- •14) Other clinically important abnormality on vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (eg, atrial fibrillation) that could compromise the study or be detrimental to the subject.
- •15) Hemoglobin level less than 11 g/dL.
研究者
相似试验
进行中（未招募）
不适用
Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes con enfermedad de Alzheimer de grado leve a moderado que son portadores de la apolipoproteína E (ApoE) e4A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 CarriersEnfermedad de AlzheimerAlzheimer DiseaseMedDRA version: 9.1Level: PTClassification code 10012271Term: Dementia Alzheimer's typeEUCTR2007-005995-14-ESWyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development800
进行中（未招募）
不适用
Ensayo de fase III, aleatorizado y multicéntrico, en sujetos mayores de 70 años con cáncer de pulmón de célula no pequeña en estadio IV, comparativo de una estrategia clásica de asignación al tratamiento (terapia de agente doble basada en carboplatino o monoterapia con docetaxel) según el performance status y la edad, con una estrategia optimizada de asignación a los mismos tratamientos según una escala de evaluación geriátrica simple, además de una evaluación geriátrica más minuciosa si fuera necesaria. - ESOGIAPacientes con cáncer de pulmón de célula no pequeña en estadío IVEUCTR2008-008372-13-ESHospital Universitario de Rennes490
进行中（未招募）
不适用
Ensayo de fase III multicéntrico, aleatorizado, controlado, con doble enmascaramiento, de emulsión catiónica oftálmica NOVA22007 (Ciclosporina al 0,1%) frente a vehículo en pacientes con síndrome del ojo seco de moderado a grave - SICCANOVEpacientes con síndrome del ojo seco de moderado a graveMedDRA version: 9.1Level: PTClassification code 10023350Term: Keratoconjunctivitis siccaEUCTR2007-000029-23-ESovagali Pharma S.A.482
进行中（未招募）
1 期
Ensayo aleatorizado, multicéntrico, de fase III, del tratamiento adyuvante en pacientes con cáncer de mama HER2-positivo con ganglios positivos o con ganglios negativos con alto riesgo, para comparar la quimioterapia más trastuzumab con la quimioterapia más trastuzumab más bevacizumab.A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with ChemotherapyPlus Trastuzumab Plus Bevacizumab - BETH(CIRG 011(TRIO)/NSABP B-44-I)Pacientes con cáncer de mama HER2-positivo con ganglios positivos resecados o con ganglios negativos de alto riesgo. Resected node-positive or high rsik node-negative invasive Her2-positive breast cancer.MedDRA version: 9.1Level: HLGTClassification code 10006291Term: Breast neoplasms malignant and unspecified (incl nipple)EUCTR2007-005182-35-ESF. Hoffmann-La Roche Ltd.3,509
进行中（未招募）
1 期
Ensayo en fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo de ustekinumab, un anticuerpo monoclonal anti-IL-12/23p40 totalmente humano, administrado por vía subcutánea, en pacientes con artritis psoriásica activaEUCTR2009-012264-14-ESCentocor B.V.